PriceTargets.com logo

Galapagos - GLPG Stock Price Target and Predictions

  • Consensus Rating: Reduce
  • Consensus Price Target: $30.75
  • Forecasted Upside: 13.38%
  • Number of Analysts: 7
  • Breakdown:
  • 2 Sell Ratings
  • 5 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$27.12 As of 12/17/2024 01:00 AM ET
▲ +0.21 (0.78%)

This chart shows the closing price for GLPG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Galapagos Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GLPG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GLPG

Analyst Price Target is $30.75
▲ +13.38% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Galapagos in the last 3 months. The average price target is $30.75, with a high forecast of $38.00 and a low forecast of $24.00. The average price target represents a 13.38% upside from the last price of $27.12.

This chart shows the closing price for GLPG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 7 polled investment analysts is to reduce stock in Galapagos. This rating has held steady since April 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
6/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
6/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
9/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
11/18/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 2 sell ratings
Ratings as of
12/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/20/2024Kepler Capital MarketsDowngradeHold ➝ Reduce
11/1/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$32.00 ➝ $30.00
9/9/2024Leerink PartnrsUpgradeHold
9/9/2024Leerink PartnersInitiated CoverageMarket Perform$24.00
8/2/2024Raymond JamesDowngradeOutperform ➝ Market Perform
4/22/2024Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$38.00 ➝ $38.00
3/28/2024Bank of AmericaReiterated RatingNeutral ➝ Underperform$41.00 ➝ $31.00
3/7/2024Morgan StanleyInitiated CoverageEqual Weight$38.00
1/2/2024Bank of AmericaBoost TargetNeutral ➝ Neutral$41.00 ➝ $44.00
8/24/2023CitigroupDowngradeBuy ➝ Neutral
8/7/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$42.00 ➝ $40.00
7/31/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$42.00
7/24/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$42.00
5/31/2023888Reiterated RatingMaintains
5/31/2023UBS GroupInitiated CoverageNeutral
5/9/2023Morgan StanleyLower Target$44.00 ➝ $42.00
5/5/2023Raymond JamesUpgradeMarket Perform ➝ Outperform
2/27/2023Morgan StanleyLower TargetEqual Weight$57.00 ➝ $44.00
2/27/2023Royal Bank of CanadaLower TargetSector Perform$53.00 ➝ $43.00
1/23/2023Jefferies Financial GroupUpgradeUnderperform ➝ Hold$49.00 ➝ $47.20
12/5/2022JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral€65.00 ➝ €50.00
11/11/2022Deutsche Bank AktiengesellschaftLower Target€50.00 ➝ €40.00
11/7/2022Royal Bank of CanadaLower TargetSector Perform$55.00 ➝ $53.00
11/7/2022Morgan StanleyLower TargetEqual Weight$63.00 ➝ $57.00
11/7/2022Raymond JamesDowngradeOutperform ➝ Market Perform
10/14/2022BarclaysLower TargetEqual Weight ➝ Equal Weight€60.00 ➝ €50.00
10/13/2022Morgan StanleyBoost TargetEqual Weight$61.00 ➝ $63.00
9/9/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$80.00 ➝ $61.00
8/15/2022Morgan StanleyBoost TargetOverweight$79.00 ➝ $80.00
8/8/2022Royal Bank of CanadaLower Target$62.00 ➝ $55.00
7/25/2022Jefferies Financial GroupDowngradeHold ➝ Underperform
7/15/2022Morgan StanleyLower TargetOverweight$80.00 ➝ $79.00
5/12/2022UBS GroupBoost TargetNeutral ➝ Neutral€52.00 ➝ €70.00
5/12/2022JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral€60.00 ➝ €65.00
2/28/2022Morgan StanleyBoost TargetOverweight$77.00 ➝ $80.00
1/28/2022Bryan, Garnier & CoUpgradeSell ➝ Buy
1/27/2022CitigroupUpgradeNeutral ➝ Buy
1/6/2022Morgan StanleyLower TargetOverweight$118.00 ➝ $77.00
11/8/2021Royal Bank of CanadaBoost TargetSector Perform$64.00 ➝ $65.00
8/27/2021UBS GroupReiterated RatingNeutral
8/19/2021BarclaysDowngradeOverweight ➝ Equal Weight
8/11/2021JPMorgan Chase & Co.Reiterated RatingNeutral
8/9/2021Royal Bank of CanadaLower TargetSector Perform$87.00 ➝ $64.00
8/6/2021Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$50.00
7/15/2021Raymond JamesSet TargetBuy$65.80
6/7/2021BarclaysReiterated RatingOverweight
5/11/2021JPMorgan Chase & Co.Reiterated RatingNeutral
5/10/2021Morgan StanleyBoost TargetOverweight$117.00 ➝ $118.00
4/20/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuy
4/14/2021BarclaysUpgradeEqual Weight ➝ Overweight
4/12/2021UBS GroupReiterated RatingNeutral
3/11/2021Morgan StanleyLower TargetOverweight$129.00 ➝ $117.00
3/2/2021BarclaysReiterated RatingEqual Weight
2/25/2021Raymond JamesUpgradeMarket Perform ➝ Outperform$100.00
2/23/2021Bank of AmericaUpgradeUnderperform ➝ Neutral$93.00 ➝ $94.00
2/19/2021Raymond JamesUpgradeMarket Perform ➝ Outperform
2/11/2021UBS GroupReiterated RatingNeutral
2/11/2021CitigroupDowngradeBuy ➝ Neutral
2/10/2021Maxim GroupDowngradeBuy ➝ Hold
1/19/2021BarclaysBoost TargetEqual Weight$85.50 ➝ $125.00
1/19/2021Morgan StanleyUpgradeEqual Weight ➝ Overweight
12/17/2020Maxim GroupLower Target$140.00 ➝ $170.00
12/17/2020Smith Barney CitigroupReiterated RatingBuy
12/17/2020Bryan, Garnier & CoDowngradeBuy ➝ Sell
11/23/2020UBS GroupReiterated RatingNeutral
11/19/2020Maxim GroupInitiated CoverageBuy$170.00
11/12/2020JPMorgan Chase & Co.Lower TargetNeutral$152.00 ➝ $142.00
10/21/2020The Goldman Sachs GroupDowngradeNeutral ➝ Sell
10/16/2020UBS GroupReiterated RatingNeutral
10/16/2020Royal Bank of CanadaLower TargetSector Perform$135.00 ➝ $131.00
10/13/2020BarclaysReiterated RatingEqual Weight
10/13/2020Morgan StanleyBoost TargetEqual Weight$158.00 ➝ $159.00
10/8/2020UBS GroupReiterated RatingNeutral
9/25/2020Stifel NicolausReiterated RatingHold
9/24/2020JPMorgan Chase & Co.Reiterated RatingNeutral
9/11/2020Stifel NicolausReiterated RatingHold
8/25/2020Jefferies Financial GroupDowngradeBuy ➝ Hold
8/24/2020HC WainwrightDowngradeBuy ➝ Neutral$270.00 ➝ $123.00
8/21/2020Morgan StanleyLower TargetEqual Weight$221.00 ➝ $158.00
8/21/2020Bank of AmericaLower TargetUnderperform$148.00 ➝ $134.00
8/19/2020CitigroupUpgradeNeutral ➝ Buy
8/19/2020Cantor FitzgeraldLower TargetNeutral$192.00 ➝ $134.00
8/19/2020BarclaysDowngradeOverweight ➝ Equal Weight
8/18/2020Stifel NicolausReiterated RatingHold$155.00
8/11/2020BarclaysReiterated RatingOverweight
8/10/2020Morgan StanleyLower TargetEqual Weight$224.00 ➝ $221.00
8/7/2020Stifel NicolausReiterated RatingHold$187.00
7/24/2020HC WainwrightReiterated RatingBuy$270.00
7/15/2020Morgan StanleyLower TargetEqual Weight$226.00 ➝ $224.00
7/10/2020Stifel NicolausDowngradeBuy ➝ Hold$298.00 ➝ $193.00
5/21/2020NomuraReiterated RatingBuy$290.00
5/21/2020HC WainwrightLower TargetBuy$302.00 ➝ $270.00
5/18/2020UBS GroupReiterated RatingNeutral
5/15/2020BarclaysReiterated RatingOverweight
4/15/2020Morgan StanleyBoost TargetEqual Weight$220.00 ➝ $226.00
4/13/2020Royal Bank of CanadaReiterated RatingHold$155.00
3/30/2020Jefferies Financial GroupUpgradeHold ➝ Buy$232.00
3/18/2020Royal Bank of CanadaUpgradeUnderperform ➝ Sector Perform$175.00 ➝ $157.00
3/2/2020JPMorgan Chase & Co.Lower TargetNeutral$205.00 ➝ $200.00
2/26/2020Morgan StanleyBoost TargetEqual Weight$215.00 ➝ $220.00
2/26/2020Nomura SecuritiesReiterated RatingBuy$209.00 ➝ $290.00
2/25/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$187.00 ➝ $192.00
2/24/2020HC WainwrightReiterated RatingBuy$205.00 ➝ $302.00
2/24/2020CitigroupDowngradeNeutral ➝ Underperform$213.00
2/24/2020Stifel NicolausReiterated RatingBuy$188.00 ➝ $298.00
2/24/2020Bank of AmericaDowngradeNeutral ➝ Underperform$213.00
2/20/2020Royal Bank of CanadaDowngradeSector Perform ➝ Underperform$175.00
1/5/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$205.00
12/20/2019UBS GroupDowngradeBuy ➝ Neutral
12/18/2019CitigroupDowngradeBuy ➝ Neutral
(Data available from 12/18/2019 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
7/21/2024
  • 1 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 5 very positive mentions
  • 25 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 5 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 6 very positive mentions
  • 15 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 5 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 5 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Galapagos logo
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Read More

Today's Range

Now: $27.12
Low: $26.64
High: $27.27

50 Day Range

MA: $27.94
Low: $25.17
High: $31.05

52 Week Range

Now: $27.12
Low: $24.16
High: $42.46

Volume

156,734 shs

Average Volume

150,838 shs

Market Capitalization

$1.79 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.23

Frequently Asked Questions

What sell-side analysts currently cover shares of Galapagos?

The following sell-side analysts have issued stock ratings on Galapagos in the last twelve months: Bank of America Co., Kepler Capital Markets, Leerink Partners, Leerink Partnrs, Morgan Stanley, Raymond James, Royal Bank of Canada, and StockNews.com.
View the latest analyst ratings for GLPG.

What is the current price target for Galapagos?

0 Wall Street analysts have set twelve-month price targets for Galapagos in the last year. Their average twelve-month price target is $30.75, suggesting a possible upside of 13.4%. Morgan Stanley has the highest price target set, predicting GLPG will reach $38.00 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $24.00 for Galapagos in the next year.
View the latest price targets for GLPG.

What is the current consensus analyst rating for Galapagos?

Galapagos currently has 2 sell ratings and 5 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for GLPG.

What other companies compete with Galapagos?

Other companies that are similar to Galapagos include Lantheus, Legend Biotech, Nuvalent, Blueprint Medicines and Elanco Animal Health. Learn More about companies similar to Galapagos.

How do I contact Galapagos' investor relations team?

Galapagos' physical mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company's listed phone number is (321) 534-2900 and its investor relations email address is [email protected]. The official website for Galapagos is www.glpg.com. Learn More about contacing Galapagos investor relations.